Search
Health

FDA approves asundexian, the first factor XIa blood thinner, to prevent repeat strokes

In a 12,327-patient trial, Sunharbo cut repeat ischemic strokes by 26% on top of antiplatelet drugs, but bleeding rose in patients over 75 and early in treatment.

A tablet and water glass on a hospital bedside table, with a faint pattern of branching blood vessels glowing on the wall behind an anonymous resting patient.
Illustration: ViewTime

The Food and Drug Administration has approved asundexian, sold as Sunharbo, for adults who have just had a mild-to-moderate ischemic stroke or a high-risk transient ischemic attack. It is the first drug in a new class of blood thinners, called factor XIa inhibitors, to reach patients in that setting. The once-daily 50 mg tablet is approved for use alongside antiplatelet therapy, the standard treatment after these events, to lower the chance of another stroke.

The label covers only noncardioembolic strokes, meaning those not caused by a clot that forms in the heart and travels to the brain. A transient ischemic attack, often called a mini-stroke, briefly blocks blood flow and frequently comes before a full stroke. Asundexian is not approved to prevent strokes in people with atrial fibrillation, the irregular heart rhythm behind many cardioembolic strokes.

That exclusion has a history. Bayer, which developed asundexian, stopped a large atrial fibrillation trial in 2023 after the drug proved less effective than apixaban, the widely used anticoagulant sold as Eliquis. That setback cast doubt on the whole drug class. Seen against it, this approval is a real recovery: the drug found a role where it adds to existing treatment instead of trying to replace an established anticoagulant.

What the trial showed

The approval rests on OCEANIC-STROKE, a phase 3 study that enrolled 12,327 adults. Participants were randomly assigned to asundexian or a placebo within 72 hours of symptom onset, and everyone also received antiplatelet therapy. Their strokes were mild to moderate, scoring 15 or lower on the NIH Stroke Scale, or they had a high-risk TIA.

Over a median of 14.2 months of treatment, asundexian lowered the risk of ischemic stroke by 26% compared with placebo. That is a relative reduction. The available summary does not give the absolute rates in each group, and those rates will matter most to doctors deciding whether the benefit justifies an extra pill and its risks for a given patient.

Bleeding is the obvious concern with any blood thinner added to antiplatelet drugs. Overall, major bleeding occurred at similar rates in the two groups. That result is the main argument for factor XIa inhibitors. They act on one part of the clotting cascade that appears to drive the growth of harmful clots more than the clotting needed to seal wounds. People born with factor XI deficiency tend to have fewer clot-related problems without frequent serious spontaneous bleeding, and that observation helped make this target attractive.

The overall bleeding figure hides two warning signs, though. Major bleeding was higher with asundexian in patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding was also more common with the drug than with placebo. Diarrhea was the most frequently reported side effect, affecting at least 3% of treated patients.

Who should not take it

The label sets several limits beyond atrial fibrillation. Asundexian is not recommended for people with moderate or severe liver impairment. It is also not recommended with medicines that both induce P-gp and strongly induce CYP3A4, because those drugs speed the body's clearance of asundexian and reduce how well it works. In practice, pharmacists will need to check a patient's full medication list before the drug is started.

The timing problem looks like the hardest part of using the drug. Ashkan Shoamanesh, a co-principal investigator of the trial at McMaster University, said the danger of a second stroke is greatest soon after the first, noting that "the risk of another potentially devastating event is highest in the days and weeks after the initial event." Yet the early weeks are also when the trial saw extra major bleeding. Doctors will have to weigh both risks during the same short window, and the balance is likely to be tightest for patients over 75, who face higher stroke risk and showed the bleeding signal.

Shoamanesh called the drug a meaningful advance. "I believe Sunharbo introduces an important new addition to poststroke care," he said in a statement.

That claim is reasonable. Treatment to prevent a second stroke has relied for years on antiplatelet drugs such as aspirin and clopidogrel, sometimes in combination, while blood-clotting factors were left mostly to anticoagulants aimed at heart-related clots. A drug that targets clotting directly in non-cardiac strokes, without a broad increase in major bleeding, fills a gap that has long existed.

The open questions are practical. The source material does not mention price, insurance coverage or when pharmacies will stock the drug, and those details will decide how widely it is used. How often doctors prescribe it to older patients, given the label's bleeding signal, will show whether the trial's overall result holds up in routine care.

Sources

Victor Chen

Victor Chen writes about health surveys, population data, and the numbers that shape public understanding of wellbeing. His coverage examines how results are measured, which groups are represented, and where uncertainty remains. He translates statistical findings into accessible language while keeping sample sizes, comparisons, and study limitations visible to readers.

View all stories